Factors associated with a patient's decision to select a cost-effective vs the most effective therapy for their own eye disease
Importance Ten percent of the Medicare Part B budget is spent on aflibercept, used to treat a
myriad of ocular neovascular diseases. A substantial portion of these costs can be attributed
to a few hundred ophthalmologists, raising concerns regarding the influence of
pharmaceutical companies on the choice of medication by a relatively small group of
clinicians. One approach to protect patients' health care interests is to include them in
deliberations on the choice of therapy for their eye disease. Objective To examine factors …
myriad of ocular neovascular diseases. A substantial portion of these costs can be attributed
to a few hundred ophthalmologists, raising concerns regarding the influence of
pharmaceutical companies on the choice of medication by a relatively small group of
clinicians. One approach to protect patients' health care interests is to include them in
deliberations on the choice of therapy for their eye disease. Objective To examine factors …